Clinical resolution of vemurafenib‐induced squamous cell carcinoma with topical 5‐fluorouracil

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|172|4|1135-1136

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.172, Iss.4, 2015-04, pp. : 1135-1136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vemurafenib-Induced Pulmonary Injury

By  

Oncology Research and Treatment, Vol. 36, Iss. 11, 2013-10 ,pp. : 685-686

Karger

Access to resources Recommend Favorite

Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

By  

Oncology, Vol. 92, Iss. 4, 2017-01 ,pp. : 221-228

Karger

Access to resources Recommend Favorite

Cisplatin, Raltitrexed, Levofolinic Acid and 5-Fluorouracil in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 232-238

Karger

Access to resources Recommend Favorite

Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 11-17

Karger

Access to resources Recommend Favorite

Vemurafenib‐Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma

By  

PEDIATRIC DERMATOLOGY, Vol. 32, Iss. 1, 2015-01 ,pp. : 153-154

John Wiley & Sons Inc

Access to resources Recommend Favorite